Stille AB: Interim Report Q2 2022

Revenues increased by 56 percent to 63.3 MSEK (40.6) and the organic growth amounted to 14 percent with revenues of 46.1 MSEK. Operating profit increased by 72 percent 8.9 MSEK (5.2).

Compared to the same quarter last year, business unit Surgical Instruments doubled its revenue driven by the acquired volume of S&T. For the same period, business unit Surgical Tables increased sales by 25 percent.

"The high demand for OR-related products continues to generate significant growth. Our continuous adjustments to price and delivery terms in combination with a stable development of OPEX, has resulted in substantially improved profitability", says Hanna Ernestam Wilkman. 

"I am proud of our ability to deliver a quarter with such strong growth and profitability despite issues in the supply chain. While these challenges are expected to continue, I am very optimistic of the company's future.", concludes Stille's CEO.

MSEK apr-jun apr-jun jan-jun jan-jun jul-jun jan-dec
2022 2021 2022 2021 2021/22 2021
Revenue 63.3 40.6 124.9 76.4 235.6 187.1
Gross Profit Margin, % 45.4 45.4 45.1 43.8 45.1 44.6
Operating Profit 8.9 5.2 16.4 9.1 27.4 20.1
Operating Profit, % 14.0 12.7 13.2 12.0 11.6 10.7
EBITDA 11.2 6.6 21.0 11.8 42.6 26.8
Net Income 7.8 2.7 13.1 6.8 22.5 16.1

Torshälla, July 15th, 2022.

This information is such information that Stille AB is obliged to disclose according to the EU's market abuse regulation. The information was, through the agency of the contact person above, rendered for publication on July 15th, 2022, kl. 08.00 (CET).